PIK3CA and colorectal carcinoma: The comparable efficacy of NVP-BEZ235 treatment in PIK3CA mutant (HCT116 and DLD-1) and PIK3CA wild type (SW480) human CRC cell lines suggests that its clinical efficacy might not be limited to those patients whose tumors contain activating PIK3CA mutations.